A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib.
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Linsitinib (Primary)
- Indications Liver cancer
- Focus Biomarker; Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 21 Dec 2011 Actual patient number (23) added as reported by ClinicalTrials.gov.
- 21 Dec 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 01 Sep 2011 Company added in the association field and additional lead trial center identified as reported by ClinicalTrials.gov.